Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates HR17031 improves blood sugar control in patients with Type 2 diabetes, indicating potential treatment advantage.
Introduction and Objective: To assess efficacy and safety of HR17031, a fixed-ratio combination of BI analogue (insulin sudelidec) and GLP-1 receptor agonist (noiiglutide), vs iGlar in pts with T2D uncontrolled on BI plus metformin, with or without another oral antidiabetic drug (OAD). Methods: In this randomized, multicenter, treat-to-target, phase 3 trial, 393 Chinese adults with T2D (HbA1c 7.5%-10.5%; previous BI + metformin ± another OAD) were randomized (1:1) to HR17031 (n = 197) or iGlar (n = 196) for 26 weeks, along with metformin. Primary outcome was HbA1c change at 26 weeks. Results: At 26 weeks, superiority was confirmed for HR17031 over iGlar in HbA1c change (-1.53% vs -0.25%, difference = -1.29%; Fig 1). HR17031 was superior to iGlar in the proportion of pts reaching HbA1c < 7.0% (48.7% vs 10.7%), HbA1c ≤ 6.5% (34.0% vs 4.1%), and HbA1c < 7.0% without weight gain (29.4% vs 3.6%). HR17031 led to weight loss in contrast to iGlar (-0.06 vs 1.35 kg). Insulin dose of HR17031 was lower than iGlar (29.9 vs 36.6 U/d). Greater reduction in FPG was reached with HR17031 than iGlar (-2.05 vs -0.68 mmol/L). All the above results were statistically significant (all P < 0.0001). Incidence of hypoglycemia was 32.3% with HR17031 and 53.3% with iGlar. No level 3 hypoglycemia was reported. No unexpected safety issues occurred. Conclusion: Compared to iGlar, HR17031 is effective and well-tolerated in pts with T2D uncontrolled on BI and OAD(s). Disclosure L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi. Q. Zhang: None. N. Mi: None. J. Zhang: None. W. Hu: None. G. Li: None. T. Lei: None. Z. Ye: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Q. Zhou: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. T. Xu: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. X. Yang: Employee; Current; Jiangsu Hengrui Pharmaceuticals Co., Ltd. Funding Jiangsu Hengrui Pharmaceuticals Co., Ltd.
No takes yet. Share an insight, caveat, or question.
CHEN et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: